Patents by Inventor Gary H. Gibbons
Gary H. Gibbons has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6821956Abstract: The invention provides for the use of oligodeoxynucleotide decoys for the prophylactic or therapeutic treatment of diseases associated with the binding of endogenous transcription factors to genes involved in cell growth, differentiation and signalling or to viral genes. By inhibiting endogenous trans-activating factors from binding transcription regulatory regions, the decoys modulate gene expression and thereby regulating pathological processes including inflammation, intimal hyperplasia, angiogenesis, neoplasia, immune responses and viral infection. The decoys are administered in amounts and under conditions whereby binding of the endogenous transcription factor to the endogenous gene is effectively competitively inhibited without significant host toxicity. The subject compositions comprise the decoy molecules in a context which provides for pharmacokinetics sufficient for effective therapeutic use.Type: GrantFiled: April 19, 2001Date of Patent: November 23, 2004Assignee: The Brigham and Women's Hospital, Inc.Inventors: Victor J. Dzau, Gary H. Gibbons, Ryuichi Morishita
-
Publication number: 20040229833Abstract: The invention provides for the use of oligodeoxynucleotide decoys for the prophylactic or therapeutic treatment of diseases associated with the binding of endogenous transcription factors to genes involved in cell growth, differentiation and signalling or to viral genes. By inhibiting endogenous trans-activating factors from binding transcription regulatory regions, the decoys modulate gene expression and thereby regulating pathological processes including inflammation, intimal hyperplasia, angiogenesis, neoplasia, immune responses and viral infection. The decoys are administered in amounts and under conditions whereby binding of the endogenous transcription factor to the endogenous gene is effectively competitively inhibited without significant host toxicity. The subject compositions comprise the decoy molecules in a context which provides for pharmacokinetics sufficient for effective therapeutic use.Type: ApplicationFiled: May 20, 2004Publication date: November 18, 2004Inventors: Victor J. Dzau, Gary H. Gibbons, Ryuichi Morishita
-
Patent number: 6774118Abstract: The invention provides for the use of oligodeoxynucleotide decoys for the prophylactic or therapeutic treatment of diseases associated with the binding of endogenous transcription factors to genes involved in cell growth, differentiation and signalling or to viral genes. By inhibiting endogenous trans-activating factors from binding transcription regulatory regions, the decoys modulate gene expression and thereby regulating pathological processes including inflammation, intimal hyperplasia, angiogenesis, neoplasia, immune responses and viral infection. The decoys are administered in amounts and under conditions whereby binding of the endogenous transcription factor to the endogenous gene is effectively competitively inhibited without significant host toxicity. The subject compositions comprise the decoy molecules in a context which provides for pharmacokinetics sufficient for effective therapeutic use.Type: GrantFiled: September 8, 1995Date of Patent: August 10, 2004Assignee: The Brigham and Women's Hospital, Inc.Inventors: Victor J. Dzau, Gary H. Gibbons, Ryuichi Morishita
-
Publication number: 20040082659Abstract: Vascular function and structure is maintained or improved by long term administration of physiologically acceptable compounds which enhance the level of endogenous nitric oxide or other intermediates in the NO induced relaxation pathway in the host.Type: ApplicationFiled: July 15, 2003Publication date: April 29, 2004Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: John P. Cooke, Victor J. Dzau, Gary H. Gibbons
-
Patent number: 6646006Abstract: Vascular function and structure is maintained or improved by long term administration of physiologically acceptable compounds which enhance the level of endogenous nitric oxide or other intermediates in the NO induced relaxation pathway in the host. Alternatively, or in combination, other compounds may be administered which provide for short term enhancement of nitric oxide, either directly or by physiological processes.Type: GrantFiled: February 1, 2002Date of Patent: November 11, 2003Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: John P. Cooke, Victor J. Dzau, Gary H. Gibbons
-
Patent number: 6642208Abstract: Vascular function and structure is maintained or improved by long term administration of physiologically acceptable compounds which enhance the level of endogenous nitric oxide or other intermediates in the NO induced relaxation pathway in the host. Alternatively, or in combination, other compounds may be administered which provide for short term enhancement of nitric oxide, either directly or by physiological processes.Type: GrantFiled: August 15, 2001Date of Patent: November 4, 2003Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: John P. Cooke, Victor J. Dzau, Gary H. Gibbons
-
Publication number: 20030186922Abstract: The invention provides for the use of oligodeoxynucleotide decoys for the prophylactic or therapeutic treatment of diseases associated with the binding of endogenous transcription factors to genes involved in cell growth, differentiation and signalling or to viral genes. By inhibiting endogenous trans-activating factors from binding transcription regulatory regions, the decoys modulate gene expression and thereby regulating pathological processes including inflammation, intimal hyperplasia, angiogenesis, neoplasia, immune responses and viral infection. The decoys are administered in amounts and under conditions whereby binding of the endogenous transcription factor to the endogenous gene is effectively competitively inhibited without significant host toxicity. The subject compositions comprise the decoy molecules in a context which provides for pharmacokinetics sufficient for effective therapeutic use.Type: ApplicationFiled: April 25, 2003Publication date: October 2, 2003Inventors: Victor J. Dzau, Gary H. Gibbons, Ryuichi Morishita
-
Publication number: 20020151592Abstract: Vascular function and structure is maintained or improved by long term administration of physiologically acceptable compounds, namely L-arginine, L-lysine, physiologically acceptable salts thereof, and polypeptide precursors thereof, which enhance the level of endogenous nitric oxide or other intermediates in the NO induced relaxation pathway in the host. In or in combination, other compounds, such as B.sub.6, folate, B.sub.12, or an antioxidant, which provide for short term enhancement of nitric oxide, either directly or by physiological processes may be employed.Type: ApplicationFiled: February 1, 2002Publication date: October 17, 2002Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: John P. COOKE , Victor J. DZAU , Gary H. GIBBONS
-
Publication number: 20020128217Abstract: The invention provides for the use of oligodeoxynucleotide decoys for the prophylactic or therapeutic treatment of diseases associated with the binding of endogenous transcription factors to genes involved in cell growth, differentiation and signaling or to viral genes. By inhibiting endogenous trans-activating factors from binding transcription regulatory regions, the decoys modulate gene expression and thereby regulating pathological processes including inflammation, intimal hyperplasia, angiogenesis, neoplasia, immune responses and viral infection. The decoys are administered in amounts and under conditions whereby binding of the endogenous transcription factor to the endogenous gene is effectively competitively inhibited without significant host toxicity. The subject compositions comprise the decoy molecules in a context which provides for pharmacokinetics sufficient for effective therapeutic use.Type: ApplicationFiled: June 5, 2001Publication date: September 12, 2002Inventors: Victor J. Dzau, Gary H. Gibbons, Ryuichi Morishita
-
Publication number: 20020091160Abstract: Vascular function and structure is maintained or improved by long term administration of physiologically acceptable compounds which enhance the level of endogenous nitric oxide or other intermediates in the NO induced relaxation pathway in the host. Alternatively, or in combination, other compounds may be administered which provide for short term enhancement of nitric oxide, either directly or by physiological processes.Type: ApplicationFiled: February 1, 2002Publication date: July 11, 2002Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: John P. Cooke, Victor J. Dzau, Gary H. Gibbons
-
Publication number: 20020052333Abstract: The invention provides for the use of oligodeoxynucleotide decoys for the prophylactic or therapeutic treatment of diseases associated with the binding of endogenous transcription factors to genes involved in cell growth, differentiation and signalling or to viral genes. By inhibiting endogenous trans-activating factors from binding transcription regulatory regions, the decoys modulate gene expression and thereby regulating pathological processes including inflammation, intimal hyperplasia, angiogenesis, neoplasia, immune responses and viral infection. The decoys are administered in amounts and under conditions whereby binding of the endogenous transcription factor to the endogenous gene is effectively competitively inhibited without significant host toxicity. The subject compositions comprise the decoy molecules in a context which provides for pharmacokinetics sufficient for effective therapeutic use.Type: ApplicationFiled: April 19, 2001Publication date: May 2, 2002Inventors: Victor J. Dzau, Gary H. Gibbons, Ryuichi Morishita
-
Publication number: 20020013288Abstract: Vascular function and structure is maintained or improved by long term administration of physiologically acceptable compounds which enhance the level of endogenous nitric oxide or other intermediates in the NO induced relaxation pathway in the host.Type: ApplicationFiled: August 15, 2001Publication date: January 31, 2002Inventors: John P. Cooke, Victor J. Dzau, Gary H. Gibbons
-
Patent number: 6337321Abstract: Vascular function and structure is maintained or improved by long term administration of physiologically acceptable compounds which enhance the level of endogenous nitric oxide or other intermediates in the NO induced relaxation pathway in the host.Type: GrantFiled: May 8, 1998Date of Patent: January 8, 2002Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: John P. Cooke, Victor J. Dzau, Gary H. Gibbons
-
Patent number: 5945452Abstract: Atherogenesis and restenosis are treated by long term administration of physiologically acceptable compounds which enhance the level of endogenous nitric oxide or other intermediates in the NO induced relaxation pathway in the host. Alternatively, or in combination, other compounds may be administered which provide for short term enhancement of nitric oxide, either directly or by physiological processes. In addition, cells may be genetically engineered to provide a component in the synthetic pathway to nitric oxide, so as to drive the process to enhance nitric oxide concentration, particularly in conjunction with the administration of a nitric oxide precursor.Type: GrantFiled: February 7, 1997Date of Patent: August 31, 1999Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: John P. Cooke, Victor J. Dzau, Gary H. Gibbons
-
Patent number: 5922687Abstract: Naked nucleic acids (DNA, RNA, and/or analogs), drugs, and/or other molecules in an extracellular environment enter cells in living intact tissue upon application of pressure to the cells and extracellular environment. Nucleic acids localize to the cell nuclei. Transfection efficiencies greater than 90% are achievable for naked DNA and RNA. A sealed enclosure, defined by an enclosing means and/or tissue, contains the cells and their extracellular environment. The enclosure is pressurized to an incubation pressure on the order of atmospheres. A protective inelastic sheath may be used to prevent distension and trauma in tissue that is part of the enclosure boundary. Suitable enclosures include pressurization chambers and organs such as blood vessels or the heart. Parts of organs, entire organs, and/or entire organisms are pressurized. Suitable target tissue types include blood vessel (in particular vein) tissue, heart, kidney, liver, and bone marrow tissue.Type: GrantFiled: November 7, 1996Date of Patent: July 13, 1999Assignee: Board of Trustees of the Leland Stanford Junior UniversityInventors: Michael J. Mann, Frank P. Diet, Victor J. Dzau, Gary H. Gibbons, Heiko Von Der Leyen
-
Patent number: 5891459Abstract: Vascular function and structure is maintained or improved by long term administration of physiologically acceptable compounds, namely L-arginine, L-lysine, physiologically acceptable salts thereof, and polypeptide precursors thereof, which enhance the level of endogenous nitric oxide or other intermediates in the NO induced relaxation pathway in the host. In or in combination, other compounds, such as B.sub.6, folate, B.sub.12, or an antioxidant, which provide for short term enhancement of nitric oxide, either directly or by physiological processes may be employed.Type: GrantFiled: November 9, 1995Date of Patent: April 6, 1999Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: John P. Cooke, Victor J. Dzau, Gary H. Gibbons
-
Patent number: 5776905Abstract: Neointimal cells are shown to express high levels of an anti-apoptotic gene, bcl-x, while the medial cells of the vessel itself express only low levels. The difference in gene expression exploited to provide for selective deletion of the neointimal cells. Apoptosis is induced by administering anti-sense bcl-x oligonucleotides to the affected vessel. Apoptosis is desirable as a treatment because it does not induce inflammation, further tissue injury or reactive hyperplasia. A significant reduction in lesion size is seen after treatment.Type: GrantFiled: August 8, 1996Date of Patent: July 7, 1998Assignee: The Board of Trustees of the Leland Stamford Junior UniversityInventors: Gary H. Gibbons, Matthew J. Pollman
-
Patent number: 5766901Abstract: The invention presents a system for inducing cells in living intact tissue, in vivo or ex vivo, to accept nucleotides from their extracellular environment and to localize those nucleotides into the cells' nuclei. This system relies on the fact that, when subjected to high pressure, cells take in nucleotides and localize those nucleotides into their nuclei with a transfection rate of greater than 90% in some cases. This invention employs various techniques for placing under high pressure either cells in isolated tissue cultures, or cells in tissues still connected to a living body.Type: GrantFiled: May 4, 1995Date of Patent: June 16, 1998Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Michael J. Mann, Frank P. Diet, Victor J. Dzau, Gary H. Gibbons, Heiko Von der Leyen
-
Patent number: 5428070Abstract: Atherogenesis and restenosis are treated by long term administration of physiologically acceptable compounds which enhance the level of endogenous nitric oxide in the host. Alternatively, or in combination, other compounds may be administered which provide for short term enhancement of nitric oxide, either directly or by physiological processes. In addition, cells may be genetically engineered to provide a component in the synthetic pathway to nitric oxide, so as drive the process to enhance nitric oxide concentration, particularly in conjunction with the administration of a nitric oxide precursor.Type: GrantFiled: June 11, 1993Date of Patent: June 27, 1995Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: John P. Cooke, Victor J. Dzau, Gary H. Gibbons